Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.34 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297734 | 0.86 | KCNE1 (0.36) | ATMKCNE1KCNQ1LMNAGAA | |
| SCHEMBL3301289 | 0.82 | KCNE1 (0.34) | ATMKCNE1KCNQ1LMNAGAA | |
| SCHEMBL27887531 | 0.81 | ATM (0.42) | ATMKCNE1KCNQ1NR3C1SLC9A1 | |
| SCHEMBL5463297 | 0.79 | LMNA (0.37) | KCNE1KCNQ1LMNACYP2C9ALDH1A1 | |
| SCHEMBL1963793 | 0.75 | KCNE1 (0.36) | ATMKCNE1KCNQ1LMNAALDH1A1 | |
| SCHEMBL3894061 | 0.74 | KCNE1 (0.35) | KCNE1KCNQ1LMNAGAAALDH1A1 | |
| SCHEMBL8800080 | 0.74 | KCNE1 (0.37) | ATMKCNE1KCNQ1LMNACYP2C9 | |
| Arsenic SCHEMBL8675880 | 0.73 | LMNA (0.34) | KCNE1KCNQ1LMNAKMT2AHTT | |
| SCHEMBL11317481 | 0.71 | KCNE1 (0.38) | ATMKCNE1KCNQ1LMNAGAA | |
| SCHEMBL15254619 | 0.70 | KCNE1 (0.43) | KCNE1KCNQ1LMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | claimed |
| WO-2016188766-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2016-12-01 | — | — | WO | claimed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-11006626-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2021-05-18 | — | — | US | disclosed |
| US-20210024485-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2021-01-28 | — | — | US | disclosed |
| US-10676452-B2 | Compound for the prophylaxis or treatment of organ damage | SULFATEQ B.V. (NL) | 2020-06-09 | — | — | US | disclosed |
| US-10426771-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | SULFATEQ B.V. (NL) | 2019-10-01 | — | — | US | disclosed |
| US-20190098890-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2019-04-04 | — | — | US | disclosed |
| US-10123529-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2018-11-13 | — | — | US | disclosed |
| US-20180280384-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | SULFATEQ B.V. (NL) | 2018-10-04 | — | — | US | disclosed |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | SULFATEQ B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | disclosed |
| US-9913841-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | SULFATEQ B.V. (NL) | 2018-03-13 | — | — | US | disclosed |
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | SULFATEQ B.V. (NL) | 2017-06-01 | — | — | US | disclosed |
| WO-2016188766-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2016-12-01 | — | — | WO | disclosed |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| EP-2935232-A1 | COMPOUNDS FOR PROTECTION OF CELLS | Sulfateq B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014098586-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | HRH4, CFTR, HRH2 | ATM 4339/4885KCNE1 2249/4885KCNQ1 1420/4885 |
| US-11006626-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | ATM 847/4885KCNE1 3257/4885KCNQ1 4434/4885 |
| US-20190098890-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | ATM 847/4885KCNE1 3257/4885KCNQ1 4434/4885 |
| US-20180280384-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | CFTR, HRH2, HRH4 | ATM 4323/4885KCNE1 2261/4885KCNQ1 1307/4885 |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | ATM 847/4885KCNE1 3257/4885KCNQ1 4434/4885 |
| US-10676452-B2 | Compound for the prophylaxis or treatment of organ damage | GLS, TXN2, SLC5A2 | ATM 2106/4885KCNE1 2148/4885KCNQ1 1881/4885 |
| US-20210024485-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | GLS, TXN2, SLC5A2 | ATM 2106/4885KCNE1 2148/4885KCNQ1 1881/4885 |
| US-10426771-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | CFTR, HRH2, HRH4 | ATM 4323/4885KCNE1 2261/4885KCNQ1 1307/4885 |
| US-10123529-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | ATM 847/4885KCNE1 3257/4885KCNQ1 4434/4885 |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | ATM 847/4885KCNE1 3257/4885KCNQ1 4434/4885 |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | LIPG, GLS, TXN2 | ATM 3043/4885KCNE1 1731/4885KCNQ1 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.